SLC28A3

Solute carrier family 28 member 3 · Q9HAS3 · SLC28A3 on Sugi Atlas →

24,908 patent compounds predicted against SLC28A3, 18,492 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Androsin (SCHEMBL464790)	0.57	4/20
SCHEMBL316940	0.53	4/20
SCHEMBL347415	0.53	4/20
SCHEMBL152729	0.51	4/20
SCHEMBL152730	0.51	4/20
Hydrochloric Acid (SCHEMBL350109)	0.51	4/20
SCHEMBL229613	0.50	4/20
SCHEMBL318115	0.49	4/20
Hydrochloric Acid (SCHEMBL318114)	0.48	4/20
Acetic Acid (SCHEMBL190256)	0.40	4/20
Ammonia Solution, Strong (SCHEMBL190255)	0.38	4/20
Ammonia Solution, Strong (SCHEMBL190257)	0.37	4/20
SCHEMBL321985	0.36	4/20
Phlorizin (SCHEMBL17290)	1.00	3/20
Phlorizin (SCHEMBL113699)	1.00	3/20
SCHEMBL166162	0.69	3/20
SCHEMBL329091	0.58	3/20
Salidroside (SCHEMBL148079)	0.58	3/20
Hydrochloric Acid (SCHEMBL316939)	0.53	3/20
SCHEMBL467695	0.48	3/20

Clinical trials — most relevant to SLC28A3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus	PHASE3	COMPLETED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors	PHASE1	RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency	nan	RECRUITING
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Characterization of Breg Cells	nan	COMPLETED
Multi-omics Study in Citrin Deficiency	nan	ACTIVE_NOT_RECRUITING
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders	nan	UNKNOWN
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Epidemiology of Gout in French Polynesia	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Individualized Antiretroviral Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC28A3 binder may also engage these)

Protein	Name	Similarity
Q8VIH3	—	0.999	Q8VIH3 →
Q9ERH8	—	0.998	Q9ERH8 →
Q62773	—	0.998	Q62773 →
SLC28A2	Sodium/nucleoside cotransporter 2	0.997	landscape →
Q9UA35	—	0.996	Q9UA35 →
Q9MZT2	—	0.996	Q9MZT2 →
E9PXX9	—	0.993	E9PXX9 →
O88627	—	0.993	O88627 →
Q62674	—	0.992	Q62674 →
SLC28A1	Sodium/nucleoside cotransporter 1	0.992	landscape →
SLC6A4	Sodium-dependent serotonin transporter	0.987	landscape →
B0JZG0	—	0.986	B0JZG0 →
O88575	—	0.985	O88575 →
Q03614	—	0.985	Q03614 →
Q9XS59	—	0.985	Q9XS59 →
Q9MYX0	—	0.985	Q9MYX0 →
B4JMC1	—	0.985	B4JMC1 →
Q08469	—	0.985	Q08469 →
P23977	—	0.985	P23977 →
Q9UGH3	—	0.984	Q9UGH3 →
Q61327	—	0.984	Q61327 →
P31652	—	0.984	P31652 →
O62667	—	0.984	O62667 →
Q9H1V8	—	0.984	Q9H1V8 →
Q0WMJ8	—	0.984	Q0WMJ8 →
Q6SZ87	—	0.984	Q6SZ87 →
Q6VVA6	—	0.983	Q6VVA6 →
Q9EPR4	—	0.983	Q9EPR4 →
A7Y2X0	—	0.983	A7Y2X0 →
Q8W469	—	0.983	Q8W469 →